BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld
Home
» Juno Therapeutics puts ALL trial on hold after additional deaths
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Juno Therapeutics puts ALL trial on hold after additional deaths
Nov. 28, 2016
By
Michael Fitzhugh
No Comments
Two cases of cerebral edema, both ending in death, led Juno Therapeutics Inc. to put a clinical hold on a phase II trial of its chimeric antigen receptor (CAR) T-cell therapy, JCAR015, for the second time in five months.
BioWorld